» Articles » PMID: 20021448

Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine

Overview
Date 2009 Dec 22
PMID 20021448
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Behavioural symptoms are a significant problem in Alzheimer's disease (AD). Symptoms including agitation/aggression and psychosis reduce patient quality of life, significantly increase caregiver burden, and often trigger nursing home placement. Underlying changes in the serotonergic, noradrenergic and cholinergic systems have been linked to some behavioural problems, however, the use of antipsychotics in this population has been associated with significant safety concerns. A role for the glutamate system in schizophrenia, as well as in anxiety and depression, has been suggested, and evidence is emerging for a role for dysfunctional glutamate neurotransmission (via N-methyl-D-aspartate (NMDA) receptors) in certain behavioural changes in dementia. For example, the NMDA receptor antagonist, memantine has been shown to improve cognition, function (activities of daily living, ADLs) and, more recently, agitation/aggression, and delusions in AD patients. To date, little information is available regarding the neurochemical basis of agitation/aggression. However, the frontal and cingulate cortices--specifically, the formation of neurofibrillary tangles in glutamatergic pyramidal neurones of these areas--are proposed as regional substrates of these behaviours. Given that memantine displays a favourable tolerability profile, it is relevant to investigate the underlying mechanism linking memantine with the behavioural elements of AD. One hypothesis proposes that memantine corrects dysfunctional glutamatergic neurotransmission in the frontal and cingulate cortices, thereby normalising pathways responsible for causing agitation. An alternative hypothesis is based on the observation that increased tangle formation is associated with agitation, and on recent studies where memantine has been shown to reduce tau phosphorylation via glycogen synthase kinase (GSK)-3 or activation of protein phosphatase (PP)-2A, which might subsequently lead to reduced agitation.

Citing Articles

Emotion Processing Dysfunction in Alzheimer's Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology.

Chaudhary S, Zhornitsky S, Chao H, van Dyck C, Li C Am J Alzheimers Dis Other Demen. 2022; 37:15333175221082834.

PMID: 35357236 PMC: 9212074. DOI: 10.1177/15333175221082834.


Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial.

Lin C, Chen P, Wang S, Lane H JAMA Netw Open. 2021; 4(4):e216156.

PMID: 33881530 PMC: 8060832. DOI: 10.1001/jamanetworkopen.2021.6156.


Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD).

Lin C, Yang H, Chen P, Wang S, Lane H Neuropsychiatr Dis Treat. 2020; 16:509-518.

PMID: 32110025 PMC: 7039065. DOI: 10.2147/NDT.S234371.


Amelioration of Scopolamine-Induced Learning and Memory Impairment by -Pinene in C57BL/6 Mice.

Lee G, Lee C, Park G, Jang J Evid Based Complement Alternat Med. 2017; 2017:4926815.

PMID: 29234406 PMC: 5687139. DOI: 10.1155/2017/4926815.


Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.

Kishi T, Matsuda Y, Iwata N Psychopharmacology (Berl). 2017; 234(14):2113-2125.

PMID: 28508107 DOI: 10.1007/s00213-017-4616-7.